A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients

Launched by BAYER · Sep 21, 2022

Keywords

ClinConnect Summary

The SMART-Finder study is looking to understand how many people with type 2 diabetes (T2DM) also have high levels of a protein called albumin in their urine, which can indicate kidney damage. This study is observational, meaning researchers will collect information without giving any specific treatments or advice. Participants will use the "myTherapy" app to track their diabetes care, and their albumin levels will be measured at the start of the study and about a year later during routine doctor visits. The goal is to see how these levels change over time in everyday healthcare settings in Germany.

To be eligible for the study, participants must be adults (18 years and older) with a self-reported diagnosis of T2DM, who are also using the "myTherapy" app to track their diabetes medications or devices. They should not have type 1 diabetes or be using insulin pumps. During the study, participants will provide information through the app, and their doctors will handle the urine tests. The study will collect data from October 2022 to December 2024, allowing researchers to gather insights on kidney health in people living with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients participating in the Chronic Kidney Disease (CKD) awareness program within myTherapy App
• • Patient self-reported diagnosis of Type 2 Diabetes Mellitus
• • Patients tracking their adherence for at least one of the following drug containing medical products/devices within myTherapy App: Metformin, Acarbose, Dipeptidyl peptidase (DDP)-4 inhibitors, Glucagon-like peptide (GLP) inhibitors, RAS inhibitors, Sodium-dependent glucose transporters 2 (SGLT2) inhibitors, Basal insulin, Finerenone (once available in Germany), Sulfonylurea, Glucose test strips
• • Adult (≥ 18 years) female, male or diverse patient
• • Signed informed consent
• Exclusion Criteria:
• • Patient self-reported diagnosis of Type 1 Diabetes Mellitus
• • Patients tracking their adherence for at least one of the following medical products: Insulin pump